Special issue: "MET as actionable target in cancer therapy".
作者信息
Ma Patrick C
机构信息
WVU Cancer Institute, West Virginia University, Morgantown, WV 26505, USA;; West Virginia Clinical and Translational Science Institute, Morgantown, WV 26505, USA.
出版信息
Ann Transl Med. 2017 Jan;5(1):1. doi: 10.21037/atm.2017.01.10.
Abstract
摘要
相似文献
1
Special issue: "MET as actionable target in cancer therapy".特刊：“MET作为癌症治疗中的可操作靶点”。
Ann Transl Med. 2017 Jan;5(1):1. doi: 10.21037/atm.2017.01.10.
2
Brain Metastases from Lung Cancer: Is MET an Actionable Target?肺癌脑转移：MET是一个可靶向治疗的靶点吗？
Cancers (Basel). 2019 Feb 26;11(3):271. doi: 10.3390/cancers11030271.
3
Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.晚期肺鳞癌的靶向组织和游离肿瘤 DNA 测序揭示了具有临床意义的可操作改变的发生率。
Clin Lung Cancer. 2019 Jan;20(1):30-36.e3. doi: 10.1016/j.cllc.2018.08.020. Epub 2018 Sep 5.
4
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target.追踪肺癌中 MET 脱瘾：走向致癌靶点的道路。
Cancer Treat Rev. 2017 Nov;60:1-11. doi: 10.1016/j.ctrv.2017.08.002. Epub 2017 Aug 20.
5
Emergence of Mutation as a Biomarker and an Actionable Target in Solid Cancers.实体瘤中突变作为生物标志物和治疗靶点的出现。
Oncologist. 2019 Dec;24(12):e1303-e1314. doi: 10.1634/theoncologist.2018-0845. Epub 2019 Jul 10.
6
Erratum: Stella, G.M. et al. Brain Metastases from Lung Cancer: Is MET an Actionable Target? 2019, , 271.勘误：斯特拉，G.M.等人。肺癌脑转移：MET是一个可操作的靶点吗？2019年，，271。
Cancers (Basel). 2019 May 10;11(5):644. doi: 10.3390/cancers11050644.
7
Actionable findings and the role of IT support: report of the ACR Actionable Reporting Work Group.可采取行动的发现及信息技术支持的作用：美国放射学会可采取行动报告工作组的报告
J Am Coll Radiol. 2014 Jun;11(6):552-8. doi: 10.1016/j.jacr.2013.12.016. Epub 2014 Jan 30.
8
Physician interpretation of genomic test results and treatment selection.医生对基因组检测结果的解读和治疗选择。
Cancer. 2018 Mar 1;124(5):966-972. doi: 10.1002/cncr.31112. Epub 2017 Nov 22.
9
HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.HGF/MET 通路异常作为人类癌症的诊断、预后和预测生物标志物。
Crit Rev Clin Lab Sci. 2019 Dec;56(8):533-566. doi: 10.1080/10408363.2019.1653821. Epub 2019 Sep 12.
10
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.KRAS 激活介导 MET 外显子 14 突变型非小细胞肺癌对靶向治疗的耐药性。
Clin Cancer Res. 2019 Feb 15;25(4):1248-1260. doi: 10.1158/1078-0432.CCR-18-1640. Epub 2018 Oct 23.
引用本文的文献
1
In vitro tools for orally inhaled drug products-state of the art for their application in pharmaceutical research and industry and regulatory challenges.用于口服吸入药物产品的体外工具——其在药物研究、产业中的应用现状及监管挑战
In Vitro Model. 2022;1(1):29-40. doi: 10.1007/s44164-021-00003-8. Epub 2021 Dec 21.
2
MicroRNA-133b expression inversely correlates with MET and can serve as an optimum predictive biomarker for patients of colorectal cancer.微小RNA-133b的表达与间质-上皮转化因子（MET）呈负相关，可作为结直肠癌患者的最佳预测生物标志物。
Transl Cancer Res. 2021 Jan;10(1):57-64. doi: 10.21037/tcr-20-2370.
3
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.肺癌靶向治疗中肿瘤异质性和耐药机制的新见解。
J Hematol Oncol. 2019 Dec 9;12(1):134. doi: 10.1186/s13045-019-0818-2.
4
MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.MET 激活与转移过程的物理动力学：以不明原发灶癌为例。
EBioMedicine. 2017 Oct;24:34-42. doi: 10.1016/j.ebiom.2017.09.025. Epub 2017 Sep 21.
本文引用的文献
1
MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.MET受体近膜外显子14可变剪接变体：新型癌症基因组预测生物标志物。
Cancer Discov. 2015 Aug;5(8):802-5. doi: 10.1158/2159-8290.CD-15-0769.
2
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.肺肉瘤样癌的下一代测序揭示了 MET 基因高频激活突变。
J Clin Oncol. 2016 Mar 10;34(8):794-802. doi: 10.1200/JCO.2015.62.0674. Epub 2015 Jul 27.
3
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.携带导致第14外显子跳跃的MET突变的IV期肺腺癌患者对MET抑制剂的反应。
Cancer Discov. 2015 Aug;5(8):842-9. doi: 10.1158/2159-8290.CD-14-1467. Epub 2015 May 13.
4
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.MET 基因通过不同的外显子 14 剪接改变而被激活，这种改变发生在多种肿瘤类型中，并赋予了对 MET 抑制剂的临床敏感性。
Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.
5
Comprehensive molecular profiling of lung adenocarcinoma.肺腺癌的全面分子分析。
Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9.
6
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.非小细胞肺癌患者对表皮生长因子受体抑制剂的耐药机制及克服耐药的新型治疗策略
Chemother Res Pract. 2012;2012:817297. doi: 10.1155/2012/817297. Epub 2012 Aug 29.
7
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.MARQUEE 研究的背景和设计：一项在先前接受过治疗的局部晚期或转移性、非鳞状、非小细胞肺癌患者中开展的 III 期、随机、双盲研究，比较 tivantinib 联合厄洛替尼与安慰剂联合厄洛替尼的疗效。
Clin Lung Cancer. 2012 Sep;13(5):391-5. doi: 10.1016/j.cllc.2012.01.003. Epub 2012 Mar 21.
8
Targeting MET in cancer: rationale and progress.靶向 MET 治疗癌症：原理与进展。
Nat Rev Cancer. 2012 Jan 24;12(2):89-103. doi: 10.1038/nrc3205.
9
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.厄洛替尼联合替沃替尼对比厄洛替尼联合安慰剂治疗既往治疗的非小细胞肺癌的随机 II 期研究。
J Clin Oncol. 2011 Aug 20;29(24):3307-15. doi: 10.1200/JCO.2010.34.0570. Epub 2011 Jul 18.
10
Hallmarks of cancer: the next generation.癌症的特征：下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
Zotero 插件